Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) represents one of the main causes of morbidity and mortality worldwide. According to the latest report of the World Health Organization,[@CIT0001] it is estimated that in 2008 in the United States 15 million people suffered from it, as well as 210 million people worldwide, with an associated mortality of 3 million people.[@CIT0002] COPD generates not only respiratory complications but also cardiovascular ones,[@CIT0003] and even osteoporosis.[@CIT0004] The deterioration in symptoms beyond the daily variation that leads to the use of additional therapy is known as Acute Exacerbation of COPD (AECOPD), being the most frequent cause of medical hospital admission in the United Kingdom with almost 15.9% of the medical hospitalizations.[@CIT0005]--[@CIT0007] In 22% of the patients with very severe COPD, exacerbation recurs, on average, 50 days after the first episode[@CIT0005] and generating a 25% deterioration of lung function,[@CIT0008] thus increasing mortality, making it five times higher in the tenth episode when compared to the first,[@CIT0006] and up to 50% when in the Intensive Care Unit.[@CIT0009] The cause of AECOPD can be infectious (40--60%)[@CIT0006] and non-infectious (smoking, pulmonary thromboembolism, and air pollution or exposure to particulate matter, PM).[@CIT0010]

Regarding exposure to PM, people exposed to environmental pollution have a greater proportion of lung dysfunction with an excess risk of 64%, which when combined with smoking increases to 129%.[@CIT0011] Likewise, it is related to higher hospital admission,[@CIT0012] deterioration of FEV1,[@CIT0013] and mortality.[@CIT0014] However, assuming that environmental exposure can exacerbate COPD, the objective of this study was to examine whether the levels of PM below 2.5 (PM2.5) and 10 microns (PM10) in the days before the symptomatic onset in adult patients with AECOPD show any change, and if that is associated with clinical presentation or outcome of an Anthonisen classification, use of antibiotic, hospitalization days, admission to ICU, and mortality.

Materials and methods {#S0002}
=====================

The protocol was approved by the institutional review board of Universidad Nacional de Colombia Number 004-033-17. Patient consent to review their medical review records was not required by the board, and thus no identifying information such as name, Identification number, and Medical number were used, and it was conducted in accordance with the principles of the Declaration of Helsinki.

Study design and participants {#S0002-S2001}
-----------------------------

A retrospective study was conducted with medical records of adult patients hospitalized at the Hospital Universitario Nacional de Colombia (Bogotá, Colombia), with an admissions diagnosis of AECOPD (ICD 10: J441 to J449) between the months of April 2016 and April 2017 and residents in places with air quality measurement. Exposure higher to the daily average levels recommended by the WHO is of 25 μg/m^3^ and 50 μg/m^3^ for PM2.5 and PM10, respectively.[@CIT0015] Computer records of the medical records with the following inclusion criteria were taken: patient over 18 years of age with a spirometric diagnosis of COPD who came in due to respiratory symptoms that suggested acute exacerbation of COPD, from a borough that has air quality measurement. Patients with other diagnoses that explained the clinical profile, missing data referring to diagnosis or treatment, and residents in areas where there is not a meteorological station into a kilometer radius or does not have PM measurements were excluded.

Sampling {#S0002-S2002}
--------

If they met the inclusion criteria, medical histories were selected by non-probabilistic convenience sampling in order of arrival. A sample size of 200 was calculated for mean differences of independent samples in order to detect mean differences between levels of PM2.5 and PM10 of 0.2 μg/m^3^/24hrs, with a standard deviation of 0.5 μg/m^3^/24 hrs, a statistical power of 80% and 95% confidence, calculated using the Epidat software (Version 4.1, Oct 2014, PAHO-WHO). Twenty percent of the estimated losses were added due to missing data, totaling 240. The record was made in EXCEL and the analysis in EPIDAT.

Bias control {#S0002-S2003}
------------

PM2.5 and PM10 values from the day of consultation, day of symptom onset, and three days prior to it were recorded. To achieve this, during hospital admission, each patient had to register their place of residence, the nearest meteorological station was located, and the average values for 24 hrs of PM2.5 and PM10 were recorded. In addition, variables of clinical presentation were recorded such as increased dyspnea, expectoration and sputum change, pleuritic pain, fever and altered state of consciousness, clinical examinations and, as outcome variables, the use of antibiotics, corticosteroids, admission to the Intensive Care Unit (ICU), days at the ICU, ventilatory support requirement, new indication for oxygen therapy, and in-patient mortality. The bias control was made by selecting those exposed in an automated way using the software. Temperature, precipitation, humidity, and alternative pollutants were registered, but these had rarely been collected, about 10%; therefore, these were excluded from the analysis.

A univariate analysis in proportions with 95% confidence intervals and central tendency and dispersion measurements considered normal distributions by Shapiro--Wilk test with a 0.05 significance that characterizes the exacerbation of COPD according to person, time, and place variables was performed. A median difference was made using the Kruskal--Wallis statistic with a significance less than 0.05. Finally, to determine the secondary objectives and control of confounding variables, a multivariate logistic regression analysis was carried out in search of the association between qualitative variables (Anthonisen Group, use of antibiotic and admission to ICU), and PM10 and 2.5 levels registered at the time of symptom onset, three days prior to the consultation and a cumulative total of four days with control of confounding variables, including variables that show statistical significance defined by the Wald statistic with a significance below 0.05. All graphs and analyses were made using the GraphPad Prism software (GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla, California, USA) through license GPS-1,030,895-EFOT-DAF4F. The final document was written according to the STROBE initiative[@CIT0016]

Results {#S0003}
=======

We reviewed 1549 medical records, finally including 250 (see [Figure 1](#F0001){ref-type="fig"}). The demographic characteristics can be seen in [Table 1](#T0001){ref-type="table"}. Twenty-eight percent of the patients did not have previous spirometric diagnosis; coexistence with asthma occurred in 5%; one-third of the patients presented pulmonary hypertension (PHT), with an average systolic pulmonary artery pressure (SPAP) of 57 mmHg measured by transthoracic echocardiography and generating pulmonary heart disease in 15% of them. PHT was more frequent among GOLD D patients (34%) when compared with GOLD A and B which had 4% and 3%, respectively (*p*=0.043) ([Figure 2](#F0002){ref-type="fig"}), as well as higher SPAP-values in GOLD D patients (*p*=0.023). In 26%, no previous exposure to smoking or combustion of biomass was identified. Regarding the clinical presentation, frequent symptoms were increased dyspnea 95% (n=238), increased expectoration 89% (n=174), and increased cough 215 (85%); fever only occurred in 42% of the cases (n=105). Regarding clinical tests, the mean of pCO~2~ was 37.5 mmHg, HCO~3~ of 27.3 mEq/Lt. Likewise, 20.8% (n=52) presented anemia according to WHO criteria,[@CIT0017] and 7.2% (n=18) presented polyglobulia. On the other hand, antibiotic was used in 62% of the patients, predominantly beta-lactam antibiotics, requiring change in 13.7% of the cases due to non-responsiveness in 40% of them (n=9), but indicating therapeutic failure in 5.6% (n=9) of all patients undergoing antibiotic use. Patients admitted without previous use of home oxygen, 40% (n=46), were prescribed this therapy after hospital discharge and in-patient mortality was 1.2 per 100 people per year (See [Table 2](#T0002){ref-type="table"}).Table 1Clinical-demographic characteristics of the patients included in the studyCharacteristicFrequency (n)Proportion (%)MeanIC95%**Age (years)**77.4\[76.1--78.8\]**Symptom duration (days)**7.8\[7.09--8.62\]**Hospitalization duration (days)**6.7\[6.23--7.25\]**Female**14758.8\[52.8--64.9\]**GOLD A**176.8 **B**218.4 **C**5622.4 **D**9036.0**Asthma**135.2\[3.0--8.7\]**Interstitial disease**135.2\[3.0--8.7\]**PHT**8734.8**OSA**3714.8\[10.9--19.8\]**Atrial fibrillation**3714.8\[10.9--19.8\]**Arterial hypertension**15562.0\[56.0--68.0\]**Diabetes mellitus**4618.4\[14.1--23.7\]**Smoking**12048.0\[42.0--54.3\]**No documented exposure**6726.80\[21.7--32.7\]**Anthonisen I**10341.2\[35.4--47.5\] **II**7831.2\[25.8--37.3\] **III**6927.6\[22.5--33.5\][^1] Table 2Course and clinical outcome of hospitalized patientsCharacteristicFrequency (n)Proportion (%)**Intensive care unit**3514.0**Ventilation**2262.8**NIMV**1568.1**Vasoactive**731.8**Community-acquired pneumonia**5220.8**ANTIBIOTIC USE**16064.0**Ampicillin/sulbactam**9559.4**Piperacillin/tazobactam**3521.9**Doxycycline**1710.6**Clarithromycin**42.5**Combination**5936.8**Clarithromycin**5593.2**Modificated**2213.7**Piperacillin/tazobactam**731.8**Meropenem**29**Inhalation therapy** **Beta-agonist**17168.4 **Albuterol**15087.7**Salmeterol**127.0**Anticholinergic**22389.2**Ipratropium. B**20391.0**Tiotropium**208.9**Corticosteroids**12148.4**Intravenous**6654.5**Oral**10284.2**Home oxygen**4639.7**Mortality**62.4[^2] Figure 1Selection algorithm of medical records. AECOPD: Acute exacerbations of chronic obstructive cardiopulmonary disease. Flow-chart of clinical records included.Figure 2Frequency and distribution of pSAP-values according to COPD severity. The distribution of the value medians for systolic pressure of the pulmonary artery (pSAP) according to the severity of the COPD classified by GOLD is shown; *p*-values are shown for the Kruskal--Wallis statistic (KW).

Environmental pollution {#S0003-S2001}
-----------------------

As high as 11.6% of the data were not recorded for the different stations. Regarding PM values, the median of PM2.5 recorded for 24 hrs was 16.4 μg/m^3^ with a range of 0.9 to 49.3 μg/m^3^, with 30% of the values above those established. For PM10, the median was 37.7 μg/m^3^ with a range of 6.7 to 103 μg/m^3^ and records higher than those of WHO for 32.3% of the cases. Likewise, the median of the daily averages of PM2.5 in the 48 hrs prior to the symptom onset was 20.1 μg/m3, compared with 15 and 16.5 μg/m^3^ for the day of the symptoms and the three previous initial days, differences that were statistically significant (*p*\<0.001). In the case of PM10, the median of these levels on the second day before the symptom onset was 46.65 μg/m^3^, compared with 39 and 35.6 on the third day after symptom onset (*p*\<0.001) (see [Figure 3](#F0003){ref-type="fig"}).Figure 3(**A, B**) PM2.5 and PM10 values, according to the day of consultation and days before the symptom onset. The medians are represented for mean values of 24 hrs for PM2.5 and PM10, according to the day of consultation, day of symptom onset (DaySx), the day before the symptom onset (Day1), two days before (Day2), and three days before the symptom onset (Day3). Dotted line: Upper limit recommended by the WHO. Kruskal--Wallis (K--W) statistic for median differences. Significant *p*-value\<0.05.

Additionally, during the day of symptom onset, patients with Anthonisen I or II presented 1.4 times more PM2.5 values greater than 25 μg/m^3^ (OR 2.45, 95% CI \[1.13--5.31\], *p*=0.019). Likewise, high levels of PM2.5 were associated with increased expectoration, purulence, pleuritic pain, and antibiotic and corticosteroid use ([Table 3](#T0003){ref-type="table"}). Regarding values for the day of consultation, no statistically significant associations were found between exposure to high levels of PM2.5 and symptoms, treatment, or outcomes. On the other hand, it was found that patients who were started on corticosteroids or those who were discharged with a new order for an oxygen therapy were associated with Anthonisen I and II (OR 3.33, 95% CI \[1.81--6.30\] and OR 2.24; % \[1.20--4.17\], respectively).Table 3Association between values of PM2.5 on the day of consultation and onset of symptoms and clinical presentation and clinical course of acute exacerbation of COPD, using a multivariate modelVariablePM 2.5PM10Consultation daySymptom onset dayConsultation daySymptom onset dayOR95% CI OR*p*OR95% CI OR*p*OR95% CI OR*P*OR95% CI OR*p*LowerUpperLowerUpperLowerUpperLowerUpper**Cough**2.130.660.2060.2061.330,374,720,6610.421,430.603.411.220.463.210.687**Expectoration**1.590.710.2560.256**4.741,0221,900,046\***0.111.710.883.341.400.653.010.389**Purulence**0.890.440.7420.742**6.582,5117,200,022\***0.181.500.822.730.980.491.950.961**Pleuritic pain**0.860.320.7670.767**3.621,2710,370,016\***0.810.910.392.080.590.211.660.317**Pneumonia**1.150.500.7470.7471.210,473,100,6920.841.080.522.210.980.432.230.955**Antibiotic**1.340.630.4430.443**2.871,177,070,022\***0.140.630.341.161.730.823.640.151**Corticosteroids**0.490.230.0570.057**2.621,076,440,035\***0.150.640.351.171.890.943.820.076**ICU**0.450.160.1440.144**7.341,0849,700,041\***0.231.450.792.671.840.873.910.113**Mortality**1.790.190.6080.6081.220,0916,110,8790.980.980.146.723.480.4825.100.217[^3][^4]

Discussion {#S0004}
==========

The role of environmental pollution in the exacerbation of COPD is increasing. In recent years, a growing number of studies have been published with the intention of evaluating the impact of exposure to PM2.5 and PM10 in AECOPD, evidencing deterioration of FEV1 and higher mortality. However, for the increase in hospital admissions, the results have been inconsistent.[@CIT0012],[@CIT0018] The main objective of this study was to identify a variation in PM levels prior to symptoms since this aspect has been insufficiently studied. A significant finding was the evidence of change in the 48 hrs prior to the symptom onset, suggesting a possible role in the pathogenesis of AECOPD, but prospective studies are required.

In addition to the effect on the symptom onset, there was also an association with the increase in expectoration, purulence, and even pain referred to as pleuritic, which leads to a higher probability of being classified as Anthonisen I-II and, therefore, an increased use of antibiotics is needed in 70% of the patients exposed to PM2.5 greater than 25mcgr/m^3^ compared to a 60% of the antibiotic use in unexposed individuals (*p*=0.016); the aforementioned is due to a collinearity effect. It should be noted that, in general, the use of antibiotics was 64%, while the one reported in previous studies was between 74.8% and 86%.[@CIT0019] Likewise, diagnosing pneumonia in patients with exacerbation of COPD of 20.8% is of interest, since their coexistence is associated with greater use of health resources, due to a long hospital stay, admission to the ICU and the performance of in-patient procedures. Such association has been described in 36.1% of the first episodes of exacerbation and in 25.6% of the subsequent hospitalizations, increasing even the risk of in-patient mortality (adjusted HR 1.20, 95% CI \[1.17--1.24\]).[@CIT0020] The association between PM, symptomatology, and antibiotic onset could be due to the fact that PM inhibits phagocytosis and increases free radicals with a subsequent lesion of the bronchial epithelium, increased inflammatory response and production of Tumor Necrosis Factor-alpha and Interleukin-1, which perpetuate inflammation affecting mucociliary movement, favoring viral and bacterial infection.[@CIT0021] On the other hand, it was found that exposure to values higher than 25mcgr/m^3^ of PM2.5, by making it more likely to be classified as Anthonisen I or II, also increases the probability of using corticosteroids as a treatment, since there is an interaction between the three variables.

On the other hand, of the patients hospitalized due to AECOPD, 16% (n=35) required admission to the Intensive Care Unit, of which approximately 70% received invasive mechanical ventilation; similar to the findings of those reported in the literature.[@CIT0022] The median stay was 4 days, which is less than that reported in previous studies which were of 6 and 8 days.[@CIT0023],[@CIT0024] Regarding environmental pollution, patients admitted to the ICU were more likely to have exposure to high levels of PM2.5 compared to those who were not admitted into the ICU; however, in these patients, there was no increased requirement for ventilatory or vasoactive support. The previously reported in-patient mortality due to exacerbation of COPD was of 7.5% and 11%;[@CIT0022]--[@CIT0025] in this study, it was 2.4%.

Another finding is the identification of patients with pulmonary tuberculosis in approximately 3.2% (n=8) of the cases. This association is noteworthy because tuberculosis can cause exacerbation, and it is also a possible etiology of COPD since the prevalence of COPD in patients with pulmonary tuberculosis is higher than that of non-infected patients, being 30.7% versus 13.9%, respectively.[@CIT0026],[@CIT0027] Following that train of thought, the study of tuberculous infection in patients with AECOPD in endemic countries is recommended.

Finally, the weaknesses of the study are those typical of retrospective studies, where memory bias could affect the dates of symptom onset, especially in patients with prolonged symptoms. Likewise, the data record can omit important details. On the other hand, 11% of the PM values were not recorded in the different stations. However, estimating this loss, the sample size was increased by 20%. Influenza epidemics were not taken into account in the statistical analysis. No microbiological study was performed for any case in order to discern between infectious or non-infectious exacerbation. Medical criteria were taken into account, so the findings described here only serve to generate hypotheses and do not express a real cause--effect relationship. On the other hand, the strength of the study is the guidance toward a more clinical scope, the impact of environmental pollution, beyond hospital admissions or mortality, being able to roughly explain a possible clinical effect and, especially, an association with greater use of antibiotics. Furthermore, it shows a possible change in the levels of external contaminants prior to the symptomatic profile, a finding not previously described in the literature.

Conclusions {#S0005}
===========

According to the findings of this study, patients hospitalized for AECOPD have increased levels of PM2.5 and PM10 in the 48 hrs prior to the symptomatic onset. In addition, elevated levels of PM during the day of symptom onset are associated with a higher finding of increased sputum volume, purulence, pleuritic pain, and use of antibiotics and corticosteroids. Taking into account the limitations of this study, prospective studies should be conducted to evaluate the associations presented here.
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[^1]: **Notes:** Clinical characteristics table at hospital admission with proportions for categorical, and dispersion measures and central tendency for the continuous ones. Anthonisen criteria which comprise three patient-reported items: increased dyspnea, increased sputum volume, and increased sputum purulence. Type I exacerbation -- all three symptoms; Type II exacerbation -- two of the three clinical symptoms; Type III exacerbation -- one of the three clinical symptoms.

    **Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; PHT, pulmonary hypertension; OSA, Obstructive Sleep Apnea Syndrome.

[^2]: **Notes:** Table with proportions of pharmacological and non-pharmacological treatments received by patients during their stay in the Hospital as well as their outcomes.

    **Abbreviation:** NIMV, non-invasive mechanical ventilation.

[^3]: **Notes:** \*Values that showed statistical significance using Wald statistic with a statistical significance of *p*\<0.05. 95% CI OR: 95% Confidence Interval for the odds ratio. Table with values of OR (Exp (B)) for multivariate logistic analysis including exposure to values higher than those recommended by the WHO of PM2.5 and PM10 for the days of consultation and the day of symptom onset. The previous one, two, and three days were not recorded since there was no significant values in them. The odds in bold are statistically significant.

[^4]: **Abbreviation:** ICU, intensive care unit.
